95 related articles for article (PubMed ID: 26768954)
21. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
Harlan LC; Clegg LX; Abrams J; Stevens JL; Ballard-Barbash R
J Clin Oncol; 2006 Feb; 24(6):872-7. PubMed ID: 16484696
[TBL] [Abstract][Full Text] [Related]
22. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
[TBL] [Abstract][Full Text] [Related]
23. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
24. Endocrine therapy alone vs. chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology).
Inal A; Akman T; Yaman S; Demir Ozturk S; Geredeli C; Bilici M; Inanc M; Harputoglu H; Demirci U; Balakan O; Yesil Cinkir H; Alici S; Uysal Sonmez O; Goksel G; Gokoz Dogu G; Umit Unal O; Tamozlu T; Buyukberber S; Melih Boruban C; Isikdogan A
J BUON; 2013; 18(1):64-9. PubMed ID: 23613390
[TBL] [Abstract][Full Text] [Related]
25. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G
Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620
[TBL] [Abstract][Full Text] [Related]
26. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Prat A; Baselga J
Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
[TBL] [Abstract][Full Text] [Related]
27. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
28. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
29. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
30. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.
Yu KD; Wu J; Shen ZZ; Shao ZM
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2201-9. PubMed ID: 22993034
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant hormonal therapy for premenopausal women with breast cancer.
Brown RJ; Davidson NE
Semin Oncol; 2006 Dec; 33(6):657-63. PubMed ID: 17145345
[TBL] [Abstract][Full Text] [Related]
32. Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients.
Cappelletti V; Celio L; Bajetta E; Allevi A; Longarini R; Miodini P; Villa R; Fabbri A; Mariani L; Giovanazzi R; Galante E; Greco M; Grazia Daidone M
Endocr Relat Cancer; 2004 Dec; 11(4):761-70. PubMed ID: 15613450
[TBL] [Abstract][Full Text] [Related]
33. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
34. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
35. Treatment patterns of elderly breast cancer patients at two Canadian cancer centres.
Angarita FA; Chesney T; Elser C; Mulligan AM; McCready DR; Escallon J
Eur J Surg Oncol; 2015 May; 41(5):625-34. PubMed ID: 25727372
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant endocrine therapy for locally advanced breast cancer.
Ma CX; Ellis MJ
Semin Oncol; 2006 Dec; 33(6):650-6. PubMed ID: 17145344
[TBL] [Abstract][Full Text] [Related]
37. Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer.
Abu-Khalf M; Pusztai L
Breast; 2013 Aug; 22 Suppl 2():S83-7. PubMed ID: 24074799
[TBL] [Abstract][Full Text] [Related]
38. Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.
Shimizu D; Ishikawa T; Tanabe M; Sasaki T; Ichikawa Y; Chishima T; Endo I
Breast Cancer; 2014 Sep; 21(5):557-62. PubMed ID: 23184499
[TBL] [Abstract][Full Text] [Related]
39. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer.
Fennessy M; Bates T; MacRae K; Riley D; Houghton J; Baum M
Br J Surg; 2004 Jun; 91(6):699-704. PubMed ID: 15164437
[TBL] [Abstract][Full Text] [Related]
40. Matched case-control survival analysis of older chinese breast cancer patients treated with surgery or primary endocrine therapy.
Suen TD; Luk WP; Fung LH; Kwong A
Cancer Treat Res Commun; 2020; 25():100227. PubMed ID: 33120314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]